TLR9 and Autoimmunity: Pharmaceutical inhibition of PKM2 by PKM2-IN can inhibit TLR4/TLR7/TLR9-induced activations of macrophages, DCs and B cells, and alleviate the pathogenesis of TLRs-mediated inflammation and autoimmunity (Figure 10).